阿哌沙班片VS利伐沙班片，谁更胜一筹？

Intermuscular venous thrombosis in the lower limbs has a high incidence rate after artificial joint replacement surgery, but it is easily overlooked because of its insidious clinical manifestations. If not properly treated, the thrombus will progress to the proximal veins, and the rate associated with pulmonary embolism is as high as 33%. At present, there is no consensus on the treatment of intermuscular venous thrombosis in the lower limbs after joint replacement due to the lack of relevant prospective and randomized controlled studies. Rivaroxaban tablets and (Eliquis) are both coagulation factor Xa inhibitors. They have the advantages of high specificity and wide indications, and have been widely used in clinical anticoagulation treatment.

So, apixaban tablets VS rivaroxaban tablets, who is better?

To compare the efficacy of rivaroxaban tablets and apixaban tablets (Eliquis) in preventing intermuscular venous thrombosis in lower limbs after joint replacement. Seventy-six patients who developed intermuscular vein thrombosis in the lower limbs after unilateral hip/knee replacement were randomly divided into two groups, with 38 patients in each group. They were given oral prophylactic anticoagulant doses of rivaroxaban and apixaban respectively. Observe the dissolution rate and progression of thrombus and the incidence of bleeding tendency events.

Results: After 1 week, 4 weeks and 12 weeks of treatment, there was no statistically significant difference in thrombolysis rate between the 2 groups (P>0.05). The apixaban group was better than rivaroxaban in the outcome of ecchymosis, and the difference was statistically significant (P<0.05). No wound infection or surrounding hematoma occurred in any patient.

It is concluded that rivaroxaban and apixaban (Eliquis) are safe and effective in preventing intermuscular vein thrombosis in the lower limbs after hip and knee arthroplasty with similar thrombolytic efficiencies. Apixaban is superior in the outcome of ecchymosis.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.